A novel model for evaluating therapies targeting human tumor vasculature and human cancer stem-like cells

Cancer Research

Volumn 73, Issue 12, 2013, Pages 3555-3565

  Burgos Ojeda, Daniela ^a   McLean, Karen ^b   Bai, Shoumei ^a   Pulaski, Heather ^b   Gong, Yusong ^b   Silva, Ines ^b   Skorecki, Karl ^c   Tzukerman, Maty ^c   Buckanovich, Ronald J ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE DEHYDROGENASE; CANCER ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOTOXIN; MONOCLONAL ANTIBODY THY1; SAPORIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER STEM CELL; CONTROLLED STUDY; DRUG TARGETING; EMBRYO; EMBRYONIC STEM CELL; FIBROBLAST; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; TERATOMA; TUMOR CELL; TUMOR NECROSIS; TUMOR VASCULARIZATION;

ANIMALS; ANTIGENS, CD31; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; EMBRYONIC STEM CELLS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTOXINS; MCF-7 CELLS; MICE; MICE, INBRED NOD; MICE, SCID; MOLECULAR TARGETED THERAPY; NEOPLASTIC STEM CELLS; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TERATOMA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84879112911     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-2845     Document Type: Article

References (35)

1. St Croix B, Rago C, Velculescu V, Traverso G, Romans KE, Montgomery E, et al. Genes expressed in human tumor endothelium. Science 2000;289:1197-202. (Pubitemid 30650733)
2. Pasqualini R, Moeller BJ, Arap W. Leveraging molecular heterogeneity of the vascular endothelium for targeted drug delivery and imaging. Semin Thromb Hemost 2010;36:343-51.
3. Zhong X, Ran YL, Lou JN, Hu D, Yu L, Zhang YS, et al. Construction of human liver cancer vascular endotheliumcDNA expression library and screening of the endothelium-associated antigen genes. World J Gastroenterol 2004;10:1402-8. (Pubitemid 39206800)
4. Allinen M, Beroukhim R, Cai L, Brennan C, Lahti-Domenici J, Huang H, et al. Molecular characterization of the tumor microenvironment in breast cancer.[see comment]. Cancer Cell 2004;6: 17-32. (Pubitemid 38903159)
5. Bhati R, Patterson C, Livasy CA, Fan C, Ketelsen D, Hu Z, et al. Molecular characterization of human breast tumor vascular cells. Am J Pathol 2008;172:1381-90. (Pubitemid 351671550)
6. Seaman S, Stevens J, Yang MY, Logsdon D, Graff-Cherry C, St Croix B. Genes that distinguish physiological and pathological angiogenesis. Cancer Cell 2007;11:539-54. (Pubitemid 46856908)
7. Buckanovich RJ, Sasaroli D, O'Brien-Jenkins A, Botbyl J,Hammond R, Katsaros D, et al. Tumor vascular proteins as biomarkers in ovarian cancer. J Clin Oncol 2007;25:852-61. (Pubitemid 350002886)
8. Lu C, Bonome T, Li Y, Kamat AA, Han LY, Schmandt R, et al. Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma. Cancer Res 2007; 67:1757-68. (Pubitemid 46383403)
9. Madden SL, Cook BP, Nacht M, Weber WD, Callahan MR, Jiang Y, et al. Vascular gene expression in nonneoplastic and malignant brain. Am J Pathol 2004;165:601-8. (Pubitemid 38971389)
10. Priebe A, Buckanovich RJ. Ovarian tumor vasculature as a source of biomarkers for diagnosis and therapy. Expert Rev Obstet Gynecol 2007;3:65-72.
11. Nanda A, St Croix B. Tumor endothelial markers: new targets for cancer therapy. Curr Opin Oncol 2004;16:44-9. (Pubitemid 38703471)
12. Burgos-Ojeda D, Rueda BR, Buckanovich RJ. Ovarian cancer stem cell markers: prognostic and therapeutic implications. Cancer Lett 2012; 322:1-7.
13. Halin C, Rondini S, Nilsson F, Berndt A, Kosmehl H, Zardi L, et al. Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature. Nat Biotechnol 2002;20:264-9. (Pubitemid 34205419)
14. Cryan LM, Rogers MS. Targeting the anthrax receptors, TEM-8 and CMG-2, for anti-angiogenic therapy. Front Biosci 2011;16: 1574-88.
15. Chaudhary A, Hilton MB, Seaman S, Haines DC, Stevenson S, Lemotte PK, et al. TEM8/ANTXR1 blockade inhibits pathological angiogenesis and potentiates tumoricidal responses against multiple cancer types. Cancer Cell 2012;21:212-26.
16. Milowsky MI, Nanus DM, Kostakoglu L, Sheehan CE, Vallabhajosula S, Goldsmith SJ, et al. Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. J Clin Oncol 2007;25:540-7. (Pubitemid 350002961)
17. Sanz L, Cuesta AM, Salas C, Corbacho C, Bellas C, Alvarez-Vallina L. Differential transplantability of human endothelial cells in colorectal cancer and renal cell carcinoma primary xenografts. Lab Invest 2009;89:91-7.
18. Bussolati B, Grange C, Tei L, Deregibus MC, Ercolani M, Aime S, et al. Targeting of human renal tumor-derived endothelial cells with peptides obtained by phage display. J Mol Med 2007;85:897-906. (Pubitemid 47077113)
19. Nor JE, Peters MC, Christensen JB, Sutorik MM, Linn S, Khan MK, et al. Engineering and characterization of functional human microvessels in immunodeficient mice. Lab Invest 2001;81:453-63. (Pubitemid 32298790)
20. Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, Hamner B, et al. A perivascular niche for brain tumor stem cells. Cancer Cell 2007; 11:69-82. (Pubitemid 46054518)
21. Tzukerman M, Rosenberg T, Reiter I, Ben-Eliezer S, Denkberg G, Coleman R, et al. The influence of a human embryonic stem cell-derived microenvironment on targeting of human solid tumor xenografts. Cancer Res 2006;66:3792-801.
22. Tzukerman M, Rosenberg T, Ravel Y, Reiter I, Coleman R, Skorecki K. An experimental platform for studying growth and invasiveness of tumor cells within teratomas derived from human embryonic stem cells. Proc Natl Acad Sci U S A 2003;100:13507-12. (Pubitemid 37444772)
23. Winer I, Wang S, Lee YE, Fan W, Gong Y, Burgos-Ojeda D, et al. F3-targeted cisplatin-hydrogel nanoparticles as an effective therapeutic that targets both murine and human ovarian tumor endothelial cells in vivo. Cancer Res 2010;70:8674-83.
24. Wu R, Hu TC, Rehemtulla A, Fearon ER, Cho KR. Preclinical testing of PI3K/AKT/mTOR signaling inhibitors in a mouse model of ovarian endometrioid adenocarcinoma. Clin Cancer Res 2011;17: 7359-72.
25. Wu R, Hendrix-Lucas N, Kuick R, Zhai Y, Schwartz DR, Akyol A, et al. Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways. Cancer Cell 2007;11:321-33. (Pubitemid 46518315)
26. Silva IA, Bai S, McLean K, Yang K, Griffith K, Thomas D, et al. Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. Cancer Res 2011;71:3991-4001.
27. Pulaski HL, Spahlinger G, Silva IA, McLean K, Kueck AS, Reynolds RK, et al. Identifying alemtuzumab as an anti-myeloid cell antiangiogenic therapy for the treatment of ovarian cancer. J Transl Med 2009;7:49.
28. Tzukerman M, Skorecki KL. A novel experimental platform for investigating cancer growth and anti-cancer therapy in a human tissue microenvironment derived from human embryonic stem cells. Methods Mol Biol 2006;331:329-46.
29. Tzukerman M, Skorecki K. A novel experimental platform for investigating tumorigenesis and anti-cancer therapy in a human microenvironment derived from embryonic stem cells. Discov Med 2003; 3:51-4.
30. Kolonin MG, Sun J, Do KA, Vidal CI, Ji Y, Baggerly KA, et al. Synchronous selection of homing peptides for multiple tissues by in vivo phage display. FASEB J 2006;20:979-81.
31. Theriault C, Pinard M, Comamala M, Migneault M, Beaudin J, Matte I, et al. MUC16 (CA125) regulates epithelial ovarian cancer cell growth, tumorigenesis and metastasis. Gynecol Oncol 2011;121: 434-43.
32. Hajitou A, Pasqualini R, Arap W. Vascular targeting: recent advances and therapeutic perspectives. Trends Cardiovasc Med 2006;16:80-8.
33. Spaeth EL, Dembinski JL, Sasser AK, Watson K, Klopp A, Hall B, et al. Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS One 2009;4:e4992.
34. McLean K, Buckanovich RJ. Myeloid cells functioning in tumor vascularization as a novel therapeutic target. Transl Res 2008; 151:59-67.
35. McLean K, Gong Y, Choi Y, Deng N, Yang K, Bai S, et al. Human ovarian carcinoma-associated mesenchymal stem cells regulate cancer stem cells and tumorigenesis via altered BMP production. J Clin Invest 2011;121:3206-19.